These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8373527)

  • 21. Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers.
    Talwar GP
    Immunol Rev; 1999 Oct; 171():173-92. PubMed ID: 10582171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The present and future of immunologic approaches to contraception.
    Talwar GP
    Int J Gynaecol Obstet; 1978; 15(5):410-4. PubMed ID: 28974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Controversial contraception: immunization against human chorionic gonadotrophin. Consultancy of Maternal Health and Family Planning of the Netherlands Association for Obstetrics and Gynecology].
    Wildschut HI
    Ned Tijdschr Geneeskd; 1996 Mar; 140(13):722-5. PubMed ID: 8668254
    [No Abstract]   [Full Text] [Related]  

  • 25. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.
    Jones SD
    IDrugs; 2010 Oct; 13(10):692-4. PubMed ID: 20878589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of immuno-contraceptive vaccines for population control. I. Hormonal immunocontraception.
    Gupta SK; Koothan PT
    Arch Immunol Ther Exp (Warsz); 1990; 38(1-2):47-60. PubMed ID: 2126920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
    Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
    Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery systems for molecular vaccination.
    Sheikh NA; al-Shamisi M; Morrow WJ
    Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
    Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
    Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving vaccine delivery using novel adjuvant systems.
    Pichichero ME
    Hum Vaccin; 2008; 4(4):262-70. PubMed ID: 18398303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microparticle-based technologies for vaccines.
    O'Hagan DT; Singh M; Ulmer JB
    Methods; 2006 Sep; 40(1):10-9. PubMed ID: 16997709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical trial of a World Health Organisation birth control vaccine.
    Jones WR; Bradley J; Judd SJ; Denholm EH; Ing RM; Mueller UW; Powell J; Griffin PD; Stevens VC
    Lancet; 1988 Jun; 1(8598):1295-8. PubMed ID: 2453766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant formulations for experimental vaccines.
    Stewart-Tull DE
    Methods Mol Med; 2003; 87():175-94. PubMed ID: 12958456
    [No Abstract]   [Full Text] [Related]  

  • 37. Particulate delivery systems for animal vaccines.
    Scheerlinck JP; Greenwood DL
    Methods; 2006 Sep; 40(1):118-24. PubMed ID: 16997719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery.
    Davis SS
    Vaccine; 2006 Apr; 24 Suppl 2():S2-7-10. PubMed ID: 16823907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Archaeobacterial ether lipid liposomes as vaccine adjuvants.
    Sprott GD; Patel GB; Krishnan L
    Methods Enzymol; 2003; 373():155-72. PubMed ID: 14714403
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunocontraception becomes a reality: the Talwar HCG vaccine.
    Coulam CB
    Am J Reprod Immunol; 1997 Feb; 37(2):151-2. PubMed ID: 9083610
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.